Evidence map›Paper›PMID 16980210›Full record

ReviewBest practice & research. Clinical rheumatology2006

Treating very early rheumatoid arthritis.

Karim Raza, Caitriona E Buckley, Mike Salmon, Christopher D Buckley

Registry-linked trialAbstract readReview
In one paragraph

Review in Best practice & research. Clinical rheumatology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00523692 (Remission Induction in Very Early Rheumatoid Arthritis), which is not on this map. Cited by 66 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 4 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00523692 phase4unknown statusnot on this mapstarted 2007, after this paper: background citation

Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy

TypeinterventionalSponsorUniversity Hospital BirminghamRan2007Enrolled20ConditionsRheumatoid ArthritisArmsEtanercept, methotrexate and depomedrone, depemedrone
3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Can the General Public Be a Proxy for an "At-Risk" Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis.Medical decision making : an international journal of the Society for Medical Decision Making · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Karim RazaRheumatology Research Group, Division of Immunity and Infection, Institute of Biomedical Research, MRC Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, UK. k.raza@bham.ac.uk
Caitriona E Buckley
Mike Salmon
Christopher D Buckley
University of Birmingham · GB

Funding

Arthritis Research UK 16390Medical Research Council G116/131
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is common and leads to joint damage due to persistent synovitis. The persistence of inflammation is maintained by hyperplastic stromal tissue, which drives the accumulation of leukocytes in the synovium. Aggressive treatment after the first 3-4 months of symptoms, with either disease modifying anti-rheumatic drugs or anti-tumor necrosis factor (TNF)-alpha therapy, reduces the rate of disease progression. However, it rarely switches off disease such that remission can be maintained without the continued need for immunosuppressive therapy. There is increasing evidence that the first few months after symptom onset represent a pathologically distinct phase of disease. This very early phase may translate into a therapeutic window of opportunity during which it may be possible to permanently switch off the disease process. The rationale for, and approaches to, treatment within this very early window are discussed.

Indexed as

AntibodiesAntirheumatic AgentsApoptosisArthritis, RheumatoidDisease ProgressionHumansLeukocytesNeutrophilsPeptides, CyclicRemission InductionRheumatoid FactorSynovitisTime FactorsTreatment OutcomeTumor Necrosis Factor-alphaAntibodiesAntirheumatic Agentscyclic citrullinated peptidePeptides, CyclicRheumatoid FactorTumor Necrosis Factor-alpha

Identifiers

PMID16980210
PMCPMC3145120
OpenAlexW2038089371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.